nach oben

Lung

Erschienen in:

16.06.2017

Clinically Promising Biomarkers in Cystic Fibrosis Pulmonary Exacerbations

verfasst von: L. Keith Scott, Robert Toner

Erschienen in: Lung | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Cystic fibrosis is a complex genetic disease hallmarked by repetitive infectious exacerbations that leads to destruction of airway architecture, acute on chronic inflammatory changes, and deterioration in lung function. Predicting an exacerbation may help preempt some of these changes by the initiation of swift antibiotic and anti-inflammatory therapy. A search for biomarkers that could predict exacerbations or help guide duration of antibiotic therapy is being aggressively sought. In this review, we discuss the most recent and promising biomarkers that hopefully will assist in the future management of the CF patient.

Waters V et al (2016) Special considerations for the treatment of pulmonary exacerbations in children with cystic fibrosis. Expert Rev Respir Med. doi:10.1080/17476348.2017.1246963 PubMed

Cogen JD et al (2017) Characterization of inpatient cystic fibrosis pulmonary exacerbations. Pediatrics 139:e20162642CrossRefPubMed

Plummer A et al (2016) Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database Syst Rev 9:CD006682PubMed

Brodt AM et al (2014) Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review. Eur Respir J 44:382–393CrossRefPubMed

Rubin JL et al (2017) Frequency and costs of pulmonary exacerbations in patients with cystic fibrosis in the United States. Curr Med Res Opin. doi:10.1080/03007995.2016.1277196

Junge S et al (2016) Factors associated with worse lung function in cystic fibrosis patients with persistent Staphylococcus aureus. PLoS ONE 11:e0166220CrossRefPubMedPubMedCentral

Louw JJ et al (2012) Serum procalcitonin is not an early marker of pulmonary exacerbation in children with cystic fibrosis. Eur J Pediatr 171:139–142CrossRefPubMed

Matouk E et al (2016) C-reactive protein in stable cystic fibrosis: an additional indicator of clinical disease activity and risk of future pulmonary exacerbations. J Pulm Respir Med 6:1000375CrossRefPubMedPubMedCentral

de Koff EM et al (2016) Development of the respiratory tract microbiota in cystic fibrosis. Curr Opin Pulm Med 22:623–628CrossRef

10.

Pittman JE et al (2014) Cystic fibrosis: NHLBI workshop on the primary prevention of chronic lung diseases. Ann Am Thorac Soc 11(Suppl 3):S161–S168CrossRefPubMedPubMedCentral

11.

Quinn RA et al (2016) Metabolomics of pulmonary exacerbations reveals the personalized nature of cystic fibrosis disease. PeerJ 4:e2174CrossRefPubMedPubMedCentral

12.

Erickson YO et al (2009) Elevated procalcitonin and C-reactive protein as potential biomarkers of sepsis in a subpopulation of thrombotic microangiopathy patients. J Clin Apher 24:150–154PubMedPubMedCentral

13.

Clark TW et al (2015) C-reactive protein level and microbial aetiology in patients hospitalised with acute exacerbation of COPD. Eur Respir J 45:76–86CrossRefPubMed

14.

Shoki AH et al (2013) Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations. Chest 144:1659–1670CrossRefPubMed

15.

Wojewodka G et al (2014) Candidate markers associated with the probability of future pulmonary exacerbations in cystic fibrosis patients. PLoS ONE 9:e88567CrossRefPubMedPubMedCentral

16.

Quon BS et al (2014) Plasma sCD14 as a biomarker to predict pulmonary exacerbations in cystic fibrosis. PLoS ONE 9:e89341CrossRefPubMedPubMedCentral

17.

Gray RD et al (2010) Sputum and serum calprotectin are useful biomarkers during CF exacerbation. J Cyst Fibros 9:193–198CrossRefPubMed

18.

Reid PA et al (2015) Measurement of serum calprotectin in stable patients predicts exacerbation and lung function decline in cystic fibrosis. Am J Respir Crit Care Med 191:233–236CrossRefPubMedPubMedCentral

19.

Salpietro C et al (2013) Nasal high-mobility group box-1 protein in children with allergic rhinitis. Int Arch Allergy Immunol 161:116–121CrossRefPubMed

20.

Entezari M et al (2012) Inhibition of high-mobility group box 1 protein (HMGB1) enhances bacterial clearance and protects against Pseudomonas aeruginosa pneumonia in cystic fibrosis. Mol Med 18:477–485CrossRefPubMedPubMedCentral

21.

Sagel SD et al (2012) Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. Am J Respir Crit Care Med 186:857–865CrossRefPubMedPubMedCentral

22.

Quon BS et al (2016) Discovery of novel plasma protein biomarkers to predict imminent cystic fibrosis pulmonary exacerbations using multiple reaction monitoring mass spectrometry. Thorax 71:216–222CrossRefPubMed

23.

Talagrand-Reboul E et al (2017) The social life of Aeromonas through biofilm and quorum sensing systems. Front Microbiol 8:37PubMedPubMedCentral

24.

Barr HL et al (2016) Diagnostic and prognostic significance of systemic alkyl quinolones for P. aeruginosa in cystic fibrosis: a longitudinal study. J Cyst Fibros. doi:10.1016/j.jcf.2016.10.005 PubMed

25.

Carmody LA et al (2013) Changes in cystic fibrosis airway microbiota at pulmonary exacerbation. Ann Am Thorac Soc 10:179–187CrossRefPubMedPubMedCentral

26.

Horck M et al (2016) Biomarkers in exhaled breath condensate are not predictive for pulmonary exacerbations in children with cystic fibrosis: results of a one-year observational study. PLoS ONE 11:e0152156. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0152156

27.

Dryahina K et al (2016) Differentiation of pulmonary bacterial pathogens in cystic fibrosis by volatile metabolites emitted by their in vitro cultures: Pseudomonas aeruginosa, Staphylococcus aureus, Stenotrophomonas maltophilia and the Burkholderia cepacia complex. J Breath Res 10:037102CrossRefPubMed

28.

Španěl P et al (2016) Do linear logistic model analyses of volatile biomarkers in exhaled breath of cystic fibrosis patients reliably indicate Pseudomonas aeruginosa infection? J Breath Res 10:036013CrossRefPubMed

29.

Ramachandran S et al (2012) A microRNA network regulates expression and biosynthesis of wild-type and DeltaF508 mutant cystic fibrosis transmembrane conductance regulator. Proc Natl Acad Sci U S A 109:13362–13367CrossRefPubMedPubMedCentral

30.

Amato F et al (2013) Gene mutation in microRNA target sites of CFTR gene: a novel pathogenetic mechanism in cystic fibrosis? PLoS ONE 8:e60448CrossRefPubMedPubMedCentral

31.

Gillen AE et al (2011) MicroRNA regulation of expression of the cystic fibrosis transmembrane conductance regulator gene. Biochem J 438:25–32CrossRefPubMedPubMedCentral

32.

Konstan MW et al (1994) Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 150:448–454CrossRefPubMed

33.

Roxo-Rosa M et al (2006) Proteomic analysis of nasal cells from cystic fibrosis patients and non-cystic fibrosis control individuals: search for novel biomarkers of cystic fibrosis lung disease. Proteomics 6:2314–2325CrossRefPubMed

Titel: Clinically Promising Biomarkers in Cystic Fibrosis Pulmonary Exacerbations
verfasst von: L. Keith Scott
Robert Toner
Publikationsdatum: 16.06.2017
Verlag: Springer US
Erschienen in: Lung / Ausgabe 4/2017
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI: https://doi.org/10.1007/s00408-017-0024-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Clinically Promising Biomarkers in Cystic Fibrosis Pulmonary Exacerbations

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Hypertonic Saline as a Useful Tool for Sputum Induction and Pathogen Detection in Cystic Fibrosis

Heart Rate Recovery After 6-min Walking Test Predicts Acute Exacerbation in COPD

Dengue Hemorrhagic Fever: A State-of-the-Art Review Focused in Pulmonary Involvement

Extraskeletal Osteosarcoma Arising from the Pleura

Letter: Phrenic Nerve Palsy Secondary to Parsonage-Turner Syndrome

Increased Soluble VCAM-1 and Normal P-Selectin in Cystic Fibrosis: a Cross-Sectional Study

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin